RxDoctor Payments Data

Rachel Dewey, DO

Family Medicine · New Roads, LANPI 1104387885

Payments from drug & device makers

$2,078in general payments, 2019–2025

Across 138 payments — averaging $15.06 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$740
  • GSK$204
  • Novo Nordisk$143
  • Takeda Pharmaceuticals U.S.A., Inc.$140
  • Pfizer$104
  • Vanda Pharmaceuticals Inc.$74
  • plus $673 from 19 others

What the payments were for

  • Food & beverage$2,078100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$2,078 in reported general payments places this provider in the 65th percentile of 1,469 family medicine providers in Louisiana.

See all family medicine providers in Louisiana

Medicare billing

Part B allowed, 2024
$17,765
Medicare patients
85
Services billed
886

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
MounjaroTirzepatide32$44,065
JardianceEmpagliflozin35$25,843
CaplytaLumateperone Tosylate15$24,067
OzempicSemaglutide16$22,488
LinzessLinaclotide29$18,352
Trelegy ElliptaFluticasone/Umeclidin/Vilanter21$13,678
MyrbetriqMirabegron17$7,345
Lantus SolostarInsulin Glargine,hum.Rec.Anlog20$2,330
Albuterol Sulfate HfaAlbuterol Sulfate82$2,155
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen69$1,201
Atorvastatin Calcium93$972
Estradiol23$858
Gabapentin79$812
Diclofenac Sodium60$791
Montelukast Sodium60$750

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCMounjaro$34$44,06532 claims
Boehringer IngelheimJardiance$13$25,84335 claims
Novo NordiskOzempic$143$22,48816 claims
AbbVieLinzess$740$18,35229 claims
GSKTrelegy Ellipta$204$13,67821 claims
Astellas Pharma US IncMyrbetriq$45$7,34517 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 1,469 family medicine providers in Louisiana.

Other family medicine in New Roads

See the full list for Louisiana

Where these figures come from

Is this you, or does something look wrong? →